Lustosa de Andrade Eliane Aleixo

Director · BG

As of 2026-09-16, Lustosa de Andrade Eliane Aleixo has 11 Form 4 transactions on record across 1 company — 6 in the trailing 12 months.

Everything this person has disclosed to the SEC on Form 4 — across every company they file for — reconstructed from the public record. A filing history, not a tip sheet.

Reconstructed holdings

Direct: $854KIndirect: $0$854Kas of 2026-09-16
  • Direct $854K
  • Indirect $0
BGdirect7,292 sh$854K

Reconstructed from this person's own Form 4 filings — the total each filing reported owning afterward, priced at the close on the as-of date shown. A filed position can lag the real one.

Direct and indirect holdings (e.g. through a trust or fund) are tagged separately, as filed.

Trades by company

BG · 11 trades
2026-09-01: Award / grant, 10 sh ($1K)2026-06-01: Award / grant, 9 sh ($1K)2026-05-20: Award / grant, 1,654 sh ($0)2026-05-15: Withheld for tax, 939 sh ($115K)2026-03-03: Award / grant, 15 sh ($2K)2025-12-01: Award / grant, 18 sh ($2K)2025-09-02: Award / grant, 21 sh ($2K)2025-06-02: Award / grant, 22 sh ($2K)2025-05-15: Withheld for tax, 529 sh ($42K)2025-05-15: Award / grant, 2,510 sh ($0)2025-03-04: Award / grant, 18 sh ($1K)

Filing ledger

DateCompanyActionShares @ priceValueOwnership ΔOwned afterFiling
11 award / exercise / gift records — not counted as purchases
DateCompanyActionSharesOwned afterFiling
2026-09-01BGAward / grant107,292Form 4
2026-06-01BGAward / grant97,282Form 4
2026-05-20BGAward / grant1,6547,273Form 4
2026-05-15BGWithheld for tax9395,619Form 4
2026-03-03BGAward / grant156,558Form 4
2025-12-01BGAward / grant186,543Form 4
2025-09-02BGAward / grant216,525Form 4
2025-06-02BGAward / grant226,504Form 4
2025-05-15BGWithheld for tax5293,972Form 4
2025-05-15BGAward / grant2,5106,482Form 4
2025-03-04BGAward / grant184,501Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.